Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019

Authors:

Abstract
The rate of new drug approvals by the US Food and Drug Administration (FDA) has increased over the past decade.1 One factor contributing to this increase in number of drugs entering the market is the expedited regulatory review programs that the FDA and European Medicines Agency (EMA) have established to speed access to new treatments.2 For example, the accelerated approval (AA) program permits the FDA to approve novel drugs for serious or life-threatening diseases on the basis of changes to surrogate measures that only are reasonably likely to predict clinical benefit.2 Surrogate measures are laboratory values that can be observed faster than clinical end points but may not accurately estimate how a patient feels, functions, or survives.3 The analogous approval pathway in the European Union (EU) is the conditional marketing authorization (CMA). Special designations in the US and Europe are also available for drugs addressing rare diseases and promote regulatory flexibility when evaluating the evidence.4